scispace - formally typeset
N

Nina Kim

Researcher at University of Rochester

Publications -  8
Citations -  447

Nina Kim is an academic researcher from University of Rochester. The author has contributed to research in topics: Immunoglobulin E & Acquired immune system. The author has an hindex of 7, co-authored 8 publications receiving 349 citations.

Papers
More filters
Journal ArticleDOI

PPARγ and the Innate Immune System Mediate the Resolution of Inflammation.

TL;DR: Novel specialized proresolving mediators—eicosanoids with critical roles in resolution—may act through PPARγ modulation to promote resolution, providing another exciting area of therapeutic potential for this receptor.
Journal ArticleDOI

The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?

TL;DR: This study investigated the ability of the SPM 17-HDHA to enhance the adaptive immune response using an OVA immunization model and a preclinical influenza vaccination mouse model, and reported the first report on the biological effects of ω-3-derived SPMs on the humoral immune response.
Journal ArticleDOI

Breaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticles.

TL;DR: It is hypothesized that platelet transcription factors are not vestigial remnants from megakaryocytes, but have important, if only partly understood functions, and at the very least, platelets are an ideal model cell to dissect out the non-genomic roles of transcription factors in nucleated cells.
Journal ArticleDOI

Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production.

TL;DR: It is demonstrated that certain SPMs inhibit the differentiation of IgE‐producing B cells, without being broadly immune suppressive, representing a novel class of potential therapeutics for IgE-driven diseases such as asthma and allergy.
Journal ArticleDOI

Lipoxin B4 Enhances Human Memory B Cell Antibody Production via Upregulating Cyclooxygenase-2 Expression.

TL;DR: LXB4 boosts memory B cell activation through COX2 and suggests that LXB4 can serve as a new vaccine adjuvant, which is a first for the first time, to the authors' knowledge, revealed.